A1EV1
~{N}-[(3-azanyloxetan-3-yl)methyl]-2-[1,1-bis(oxidanylidene)-3,5-dihydro-2~{H}-1$l^{6},4-benzothiazepin-4-yl]-6-methyl-quinazolin-4-amine
| Created: | 2025-08-22 |
| Last modified: | 2026-01-14 |
Find Related PDB Entry |
|---|
Find related ligands: |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 56 |
| Chiral Atom Count | 0 |
| Bond Count | 60 |
| Aromatic Bond Count | 17 |
Chemical Component Summary | |
|---|---|
| Name | ~{N}-[(3-azanyloxetan-3-yl)methyl]-2-[1,1-bis(oxidanylidene)-3,5-dihydro-2~{H}-1$l^{6},4-benzothiazepin-4-yl]-6-methyl-quinazolin-4-amine |
| Synonyms | Ziresovir |
| Systematic Name (OpenEye OEToolkits) | ~{N}-[(3-azanyloxetan-3-yl)methyl]-2-[1,1-bis(oxidanylidene)-3,5-dihydro-2~{H}-1$l^{6},4-benzothiazepin-4-yl]-6-methyl-quinazolin-4-amine |
| Formula | C22 H25 N5 O3 S |
| Molecular Weight | 439.531 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | CACTVS | 3.385 | Cc1ccc2nc(nc(NCC3(N)COC3)c2c1)N4CC[S](=O)(=O)c5ccccc5C4 |
| SMILES | OpenEye OEToolkits | 2.0.7 | Cc1ccc2c(c1)c(nc(n2)N3CCS(=O)(=O)c4ccccc4C3)NCC5(COC5)N |
| Canonical SMILES | CACTVS | 3.385 | Cc1ccc2nc(nc(NCC3(N)COC3)c2c1)N4CC[S](=O)(=O)c5ccccc5C4 |
| Canonical SMILES | OpenEye OEToolkits | 2.0.7 | Cc1ccc2c(c1)c(nc(n2)N3CCS(=O)(=O)c4ccccc4C3)NCC5(COC5)N |
| InChI | InChI | 1.06 | InChI=1S/C22H25N5O3S/c1-15-6-7-18-17(10-15)20(24-12-22(23)13-30-14-22)26-21(25-18)27-8-9-31(28,29)19-5-3-2-4-16(19)11-27/h2-7,10H,8-9,11-14,23H2,1H3,(H,24,25,26) |
| InChIKey | InChI | 1.06 | GAAICKUTDBZCMT-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB15145 |
|---|---|
| Name | Ziresovir |
| Groups | investigational |
| Description | Ziresovir is under investigation in clinical trial NCT03699202 (Anti-RSV Study in Chinese Patients (ASCENT)). |
| Synonyms | Ziresovir |
| Categories |
|
| CAS number | 1422500-60-4 |














